Stock fact sheet · data as of
Alzamend Neuro Inc (ALZN): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is ALZN undervalued?
At 1.28 (close of 16 Oct 2026), ALZN has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -2.03 and it pays no dividend), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.
The nightly engine files ALZN under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for ALZN
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.0867 | -93% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Alzamend Neuro Inc scores only 1 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.4/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -1196.4%, ROE -1196.4%, ROA -421.9% - with debt at 0.00 times equity and negative free cash flow.
Alzamend Neuro Inc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 1/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 1 / 9 | ROIC | -1196.4% |
|---|---|---|---|
| GLS Moat | 1.4 / 10 | ROE | -1196.4% |
| Debt / equity | 0.00 | ROA | -421.9% |
| Free-cash-flow yield | -110.8% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 23: No options
No options are listed on Alzamend Neuro Inc in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 23) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 15k shares a day on a market cap of $6M, with a beta of 0.19 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 2 / 20 | Piotroski 1/9 | |
| Moat | 2 / 15 | moat 1.4/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 15k shares/day, $6M cap, beta 0.19 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 8 Dec 2026, 53 days away - outside the window of a 30-45-day put sold today.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Alzamend Neuro Inc by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| NCNA NuCana plc | 1.02 | 14.66 | +93% | 33No options | $6M |
| ENVB Enveric Biosciences, Inc. | 1.39 | 12.40 | +89% | 37No options | $6M |
| TRAW Traws Pharma, Inc. | 0.4012 | - | - | 28No options | $6M |
| RVPH Reviva Pharmaceuticals Holdings, Inc. | 0.4782 | 3.09 | +85% | 36Weak | $6M |
| NRSN NeuroSense Therapeutics Ltd. | 3.17 | - | - | 21No options | $6M |
| VBIO Valion Bio, Inc. | 1.45 | 5.14 | +72% | 36No options | $6M |
| IMNN Imunon, Inc. | 1.06 | 3.07 | +65% | 31No options | $6M |
| CUBT Curative Biotechnology, Inc. | 0.9500 | - | - | 24No options | $6M |
| ACXP Acurx Pharmaceuticals, Inc. | 1.17 | 5.07 | +77% | 38No options | $7M |
| APUS Apimeds Pharmaceuticals US, Inc | 4.39 | - | - | 23No options | $7M |
| IMRN Immuron Limited | 1.03 | - | - | 30No options | $7M |
| FBLG FibroBiologics, Inc. Common Stock | 1.00 | 0.7260 | -38% | 14No options | $7M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ALZN
Is ALZN undervalued right now?
The GLS models could not value ALZN (the company lost money over the last twelve months, EPS -2.03 and it pays no dividend), so there is no fair value or margin of safety to compare the price of 1.28 against.
What is the Wheel Score of ALZN and what does it mean?
ALZN has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for ALZN?
None of the nine GLS models produced a positive value for ALZN (the company lost money over the last twelve months, EPS -2.03 and it pays no dividend), so there is no GLS fair value tonight.
When does Alzamend Neuro Inc report earnings next?
The next earnings report is due on 8 Dec 2026, 53 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ALZN have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on ALZN, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.